Floatz logo

Montanide Isa-51

Bone Cancer

National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Bone Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Actuate Therapeutics Inc.
Phase 2B
Inno-206
Actuate Therapeutics Inc.
Phase 2B
Angiotensin-(1-7)
Wake Forest University Health Sciences
Phase 2CCC
Enbrel
The University of Texas Health Science Center at San Antonio
Phase 2/3CCC
Carboplatin
Actuate Therapeutics Inc.
Phase 2CCC

View all 14 →

Same molecule, other indications

Montanide Isa-51 is also rated in:

Advanced Renal Cell CancerDormant
BB
Indicative ·
64 / 100
View asset →
MelanomaDormant
BB
Indicative ·
64 / 100
View asset →
Stage IV MelanomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →